Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibodyconjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors

被引：0

作者：

Diamond, Jennifer Robinson

Henry, Jason Timothy

Falchook, Gerald Steven

Olszanski, Anthony J.

Singh, Harshabad

Leonard, E. Jane

Gregory, Richard C.

Appleman, Vicky A.

Gibbs, John

Harbison, Carole

Li, Cong

Sapiro, Jessica M.

Yoneyama, Tomoki

Parent, Alexander A.

Chung, Vincent

机构：

[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[2] Hlth ONE, Sarah Cannon Res Inst, Denver, CO USA

[3] Fox Chase Canc Ctr, Philadelphia, PA USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[6] City Hope Natl Med Ctr, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2690

引用

页数：1